雄激素受体抑制可增加前列腺癌中I类主要组织相容性复合体的表达并改善免疫反应。
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
作者信息
Chesner Lisa N, Polesso Fanny, Graff Julie N, Hawley Jessica E, Smith Alexis K, Lundberg Arian, Das Rajdeep, Shenoy Tanushree, Sjöström Martin, Zhao Faming, Hu Ya-Mei, Linder Simon, Chen William S, Hawkins Reed M, Shrestha Raunak, Zhu Xiaolin, Foye Adam, Li Haolong, Kim Lisa M, Bhalla Megha, O'loughlin Thomas, Kuzuoglu-Ozturk Duygu, Hua Junjie T, Badura Michelle L, Wilkinson Scott, Trostel Shana Y, Bergman Andries M, Ruggero Davide, Drake Charles G, Sowalsky Adam G, Fong Lawrence, Cooperberg Matthew R, Zwart Wilbert, Guan Xiangnan, Ashworth Alan, Xia Zheng, Quigley David A, Gilbert Luke A, Feng Felix Y, Moran Amy E
机构信息
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
出版信息
Cancer Discov. 2025 Mar 3;15(3):481-494. doi: 10.1158/2159-8290.CD-24-0559.
Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.
对于免疫“冷”肿瘤（如前列腺癌）的免疫疗法选择有限。我们发现雄激素受体（AR）下调主要组织相容性复合体I类（MHCI）的表达/抗原呈递，并且抑制AR可改善T细胞反应和肿瘤控制。这表明联合使用AR抑制剂和检查点阻断的治疗方法可能会改善患者的肿瘤免疫监测和抗肿瘤免疫力。
Zotero 插件